1. Inicio
  2. Investigación
  3. Grupos de investigación
  4. Biomarcadores y Abordaje Personalizado del Cáncer (BioPAC)

Biomarcadores y Abordaje Personalizado del Cáncer (BioPAC)

Buscador de publicaciones

Sólo se han incluido artículos originales, editoriales y revisiones.

  • Ruz-Caracuel I, Pedraza-Arevalo S, Alonso-Gordoa T, Molina-Cerrillo J, Earl J, Sainz B Jr.

    Everything you ever wanted to know about cancer stem cells in neuroendocrine neoplasms but were afraid to ask.

    Endocrine Oncology (bristol, England) . 4(1): .

    [doi:10.1530/EO-24-0006]

  • Muñoz Couselo E, Cañueto J, Jerviz Guía V, López López AM, Bermejo Segú JO, García Castaño A, Puig Sardá S, Sanmartín Jiménez O, Soria Rivas A, Gratal P, Pardo MT, Rogado Á, Berrocal Jaime A.

    Recommendations for the management of cutaneous squamous cell carcinoma: a systematic multidisciplinary Delphi consensus approach.

    CLINICAL & TRANSLATIONAL ONCOLOGY . : .

    [doi:10.1007/s12094-024-03826-5]

  • Fabra D, Melones-Herrero J, Velazquez-Gutierrez J, Matesanz AI, Aliseda PD, Figueiras S, Aguilar-Rico F, Calés C, Sánchez-Pérez I, Quiroga AG.

    A select thiosemicarbazone copper(II) complex induces apoptosis in gastric cancer and targets cancer stem cells reducing pluripotency markers.

    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY . 280: 116994-116994.

    [doi:10.1016/j.ejmech.2024.116994]

  • Salazar J, Arranz MJ, Martin-Broto J, Bautista F, Martínez-García J, Martínez-Trufero J, Vidal-Insua Y, Echebarria-Barona A, Díaz-Beveridge R, Valverde C, Luna P, Vaz-Salgado MA, Blay P, Álvarez R, Sebio A.

    Pharmacogenetics of Neoadjuvant MAP Chemotherapy in Localized Osteosarcoma: A Study Based on Data from the GEIS-33 Protocol.

    Pharmaceutics . 16(12): .

    [doi:10.3390/pharmaceutics16121585]

  • Vaz-Salgado MA, Albarran V, Pozas J, Ferreiro R, Pachón V, Longo F, Rodriguez M, Barreto E, Earl J.

    Single nucleotide polymorphisms: impact on susceptibility to chemotherapy in patients with colorectal cancer.

    Future Science Oa . 10(1): 2428077-2428077.

    [doi:10.1080/20565623.2024.2428077]

  • Sotoca Rubio P, Barrill Corpa AM, Alia Navarro V, Pérez de Aguado Rodríguez P, Moreno Doval J, Calvo Pérez JC, Guerrero Serrano P, García Merino C, García de Quevedo Suero C, Fernández-Fradejas J, Serrano Domingo JJ, Martínez Delfrade Í, Morón García BI, Ferreiro Monteagudo MR, De Frutos González B.

    Efficacy and safety of regorafenib for the treatment of metastatic colorectal cancer in routine clinical practice: results from a Spanish hospital.

    Frontiers in Oncology . 14: 1446945-1446945.

    [doi:10.3389/fonc.2024.1446945]

  • Llach J, Luzko I, Earl J, Barreto E, Rodríguez-Garrote M, Lleixà M, Herrera-Pariente C, Fernández G, Munoz J, Bonjoch L, Saurí T, Ausania F, Ocaña T, Moreno L, Grau E, Oriola J, Alvarez-Mora MI, Herreros-Villanueva M, Castellví-Bel S, Balaguer F, Bujanda L, Moreira L.

    Should We Offer Universal Germline Genetic Testing to All Patients with Pancreatic Cancer? A Multicenter Study.

    Cancers . 16(22): .

    [doi:10.3390/cancers16223779]

  • Mondaza-Hernandez JL, Hindi N, Fernandez-Serra A, Ramos R, Gonzalez-Cámpora R, Gómez-Mateo MC, Martinez-Trufero J, Lavernia J, Lopez-Pousa A, Laínez N, Martinez-Garcia J, Valverde C, Vaz-Salgado MÁ, Garcia-Plaza G, Marin-Borrero I, Carrillo-Garcia J, Martin-Ruiz M, Romero P, Gutierrez A, López-Guerrero JA, Moura DS, Martin-Broto J.

    Exploratory analysis of immunomodulatory factors identifies L1CAM as a prognostic marker in alveolar soft-part sarcoma.

    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY . 16: .

    [doi:10.1177/17588359241293951]

  • Márquez-Rodas I, Álvarez A, Arance A, Valduvieco I, Berciano-Guerrero MÁ, Delgado R, Soria A, López Campos F, Sánchez P, Luis Romero J, Martin-Liberal J, Lucas A, Díaz-Beveridge R, Conde-Moreno AJ, Álamo de la Gala MDC, García-Castaño A, José Prada P, González Cao M, Puertas E, Vidal J, Foro P, Aguado de la Rosa C, Corona JA, Cerezuela-Fuentes P, López P, Luna P, Aymar N, Puértolas T, Sanagustín P, Berrocal A.

    Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study).

    Neuro-Oncology . 26(11): 2074-2083.

    [doi:10.1093/neuonc/noae116]

  • Rivera F, Longo F, Martín Richard M, Richart P, Alsina M, Carmona A, Custodio AB, Fernández Montes A, Gallego J, Fleitas Kanonnikoff T.

    SEOM-GEMCAD-TTD clinical guideline for the diagnosis and treatment of gastric cancer (2023).

    CLINICAL & TRANSLATIONAL ONCOLOGY . 26(11): 2826-2840. Nº de citas: 1

    [doi:10.1007/s12094-024-03600-7]

  • Rivas AS, Álvarez YE, Cordellat AB, Tarruella MM, Mata KM, de la Cámara MM, Del Mar Muñoz Sánchez M, Poves MZ, Zambrano CB, Gutierrez LC.

    SEOM clinical guidelines for cancer anorexia-cachexia syndrome (2023).

    CLINICAL & TRANSLATIONAL ONCOLOGY . 26(11): 2866-2876.

    [doi:10.1007/s12094-024-03502-8]

  • Buchholz M, Lausser L, Schenk M, Earl J, Lawlor RT, Scarpa A, Sanjuanbenito A, Carrato A, Malats N, Tjaden C, Giese NA, Büchler M, Hackert T, Kestler HA, Gress TM.

    Combined analysis of a serum mRNA/miRNA marker signature and CA 19-9 for timely and accurate diagnosis of recurrence after resection of pancreatic ductal adenocarcinoma: A prospective multicenter cohort study.

    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL . : .

    [doi:10.1002/ueg2.12676]

  • Alcala S, Serralta San Martin G, Muñoz-Fernández de Legaria M, Moreno-Rubio J, Salinas S, López-Gil JC, Rojo López JA, Martínez Alegre J, Cortes Bandy DA, Zambrana F, Jiménez-Gordo AM, Casado E, López-Gómez M, Sainz B.

    Autofluorescent Cancer Stem Cells: Potential Biomarker to Predict Recurrence in Resected Colorectal Tumors.

    Cancer Research Communications . 4(10): 2575-2588.

    [doi:10.1158/2767-9764.CRC-24-0188]

  • Chung HC, Saada-Bouzid E, Longo F, Yanez E, Im SA, Castanon E, Desautels DN, Graham DM, Garcia-Corbacho J, Lopez J, Dutcus C, Okpara CE, Ghori R, Jin F, Groisberg R, Korakis I.

    Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple-negative breast cancer: Results from the triple-negative breast cancer cohort of the phase 2 LEAP-005 Study.

    CANCER . 130(19): 3278-3288.

    [doi:10.1002/cncr.35387]

  • Budillon A, Leone A, Passaro E, Silvestro L, Foschini F, Iannelli F, Roca MS, Macchini M, Bruzzese F, Garcia Bermejo ML, Rodriguez Garrote M, Tortora G, Milella M, Reni M, Fuchs C, Hewitt E, Kubiak C, Di Gennaro E, Giannarelli D, Avallone A.

    Randomized phase 2 study of valproic acid combined with simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic pancreatic adenocarcinoma patients: the VESPA trial study protocol.

    Bmc Cancer . 24(1): 1167-1167.

    [doi:10.1186/s12885-024-12936-w]

  • Niedra, Helvijs, Peculis, Raitis, Saksis, Rihards, Mandrika, Ilona, Vilisova, Sofija, Nazarovs, Jurijs, Breiksa, Austra, Gerina, Aija, Earl, Julie, Ruz-Caracuel, Ignacio, Rosas, Marta Gabriela, Pukitis, Aldis, Senterjakova, Natalja, Rovite, Vita.

    Tumor and a-SMA-expressing stromal cells in pancreatic neuroendocrine tumors have a distinct RNA profile depending on tumor grade

    MOLECULAR ONCOLOGY . : .

    [doi:10.1002/1878-0261.13727]

  • Mirasierra M, Fernández-Pérez A, Lizarbe B, Keiran N, Ruiz-Cañas L, Casarejos MJ, Cerdán S, Vendrell J, Fernández-Veledo S, Vallejo M.

    Alx3 deficiency disrupts energy homeostasis, alters body composition, and impairs hypothalamic regulation of food intake.

    CELLULAR AND MOLECULAR LIFE SCIENCES . 81(1): 343-343.

    [doi:10.1007/s00018-024-05384-z]

  • Albarrán V, Guerrero P, de Quevedo CG, González C, Chamorro J, Rosero DI, Moreno J, Calvo JC, de Aguado PP, Alía V, Sotoca P, Barrill AM, Román MS, Álvarez-Ballesteros P, Serrano JJ, Soria A, Olmedo ME, Saavedra C, Cortés A, Gómez A, Lage Y, Ruiz Á, Ferreiro MR, Longo F, Garrido P, Gajate P.

    Negative association of steroids with immunotherapy efficacy in a multi-tumor cohort: time and dose-dependent.

    CANCER IMMUNOLOGY IMMUNOTHERAPY . 73(10): 186-186. Nº de citas: 2

    [doi:10.1007/s00262-024-03772-9]